Anbenitamab Set to Lead as First Bispecific mAb in China's HER2+ Gastric Cancer Market: GlobalData
China’s NMPA has accepted Alphamab Oncology’s NDA for KN026 (Anbenitamab), which could become the first bispecific mAb for HER2-positive gastric and GEJ cancer, according to GlobalData.
NDA | 25/09/2025 | By Dineshwori | 173
Antheia Appoints Richard Sherwin as Head of Commercialization
Antheia Appoints Richard Sherwin as Head of Commercialization
NDA | 18/08/2023 | By Sudeep Soparkar | 852
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
NDA | 08/08/2023 | By Sudeep Soparkar | 651
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy